Rapid Dose Therapeutics Receivables

Rapid Dose Therapeutics posts a receivables of $130K as of August 2026. That compares with $690K in the prior-year period — down 80.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Rapid Dose Therapeutics's receivables was $690K. The latest reading is $130K — a 80.6% year-over-year decrease (period ending August 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Rapid Dose Therapeutics's financial statement story. At $130K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RDTCF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Rapid Dose Therapeutics's other metric pages and overview cover the third.

Judging Rapid Dose Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $130K here, then scan peer and history charts to see if the gap is persistent.